Alpine Immune Sciences

OverviewSuggest Edit

Founded in 2015 by a team responsible for the FDA’s approval of the world’s first cancer immunotherapy and experts in the field of recombinant protein based immunotherapies. Alpine Immune Sciences was created to capitalize on our unique understanding of immunology, modifying the complexities of the immune synapse for the benefit of patients living with cancer, autoimmune disorders, and other diseases.
TypePrivate
Founded2015
HQSeattle, WA, US
Websitealpineimmunesciences.com

Latest Updates

Employees (est.) (Dec 2018)48(+27%)
Revenue (FY, 2020)$9.3 M(+437%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Alpine Immune Sciences

Mitchell H. Gold

Mitchell H. Gold

Executive Chairman & CEO
Robert Conway

Robert Conway

Director
Min Cui

Min Cui

Director
Christopher Peetz

Christopher Peetz

Director
Natasha Hernday

Natasha Hernday

Director
Paul Rickey

Paul Rickey

Chief Financial Officer
Show more

Alpine Immune Sciences Office Locations

Alpine Immune Sciences has an office in Seattle
Seattle, WA, US (HQ)
188 E Blaine St #200
Show all (1)

Alpine Immune Sciences Financials and Metrics

Summary Metrics

Founding Date

2015

Alpine Immune Sciences total Funding

$49.3 m

Alpine Immune Sciences latest funding size

$48 m

Time since last funding

5 years ago

Alpine Immune Sciences investors

Alpine Immune Sciences's latest funding round in June 2016 was reported to be $48 m. In total, Alpine Immune Sciences has raised $49.3 m
Show all financial metrics

Alpine Immune Sciences Revenue

Alpine Immune Sciences's revenue was reported to be $9.34 m in FY, 2020
USD

Revenue (FY, 2020)

9.3m

Net income (FY, 2020)

(27.9m)

EBIT (FY, 2020)

(28.7m)

Cash (31-Dec-2020)

35.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

492.0k3.0m1.7m705.0k1.7m9.3m

Revenue growth, %

500%(41%)

General and administrative expense

441.0k1.1m6.1m8.4m9.5m10.9m

R&D expense

422.0k3.0m10.6m29.0m35.8m27.2m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

567.0k289.0k1.1m688.0k

General and administrative expense

1.4m1.8m2.4m2.2m1.9m2.8m2.6m1.9m2.1m1.9m1.9m2.3m2.6m2.5m1.8m3.3m

R&D expense

4.5m4.3m5.6m6.4m5.7m2.8m359.0k2.8m3.8m5.7m10.5m10.4m10.2m9.5m4.9m7.1m

Operating expense total

5.9m6.1m7.9m8.6m7.5m5.5m3.0m4.7m5.9m7.6m12.4m12.7m12.7m12.0m6.7m10.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

25.0m11.8m8.0m10.7m16.1m35.0m

Prepaid Expenses

432.0k36.0k1.3m1.2m1.7m1.5m

Current Assets

87.7m11.9m82.5m53.5m42.3m107.1m

PP&E

223.0k740.0k1.1m1.2m1.6m1.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(22.8m)(31.5m)(7.8m)(36.5m)(41.9m)(27.9m)

Depreciation and Amortization

66.0k241.0k388.0k468.0k578.0k

Accounts Payable

65.0k927.0k66.0k1.5m816.0k(491.0k)

Cash From Operating Activities

(19.2m)(26.3m)(16.6m)(28.4m)(35.3m)30.1m
USDQ2, 2015

Financial Leverage

1.1 x
Show all financial metrics

Alpine Immune Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Alpine Immune Sciences Online and Social Media Presence

Embed Graph

Alpine Immune Sciences News and Updates

Thinking about buying stock in Tonix Pharmaceuticals, Alpine Immune Sciences, Allied Esports Entertainment, Boxlight Corp, or United States Steel?

NEW YORK, June 18, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, ALPN, AESE, BOXL, and X. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Alpine Immune Sciences Blogs

Alpine Immune Sciences Announces Participation in Fireside Chat at the 4th Annual Evercore ISI HealthCONx Conference

SEATTLE --(BUSINESS WIRE)--Nov. 22, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune and inflammatory diseases, today announced the company will participate in a fireside chat at

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results

Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results Content Import Wed, 11/10/2021 - 16:07 Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2021 Financial Results November 10, 2021 This r…

Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

- ALPN-303 demonstrates superior immunomodulatory activity and efficacy in preclinical models - - Phase 1 study to begin Q4 2021 - SEATTLE --(BUSINESS WIRE)--Nov. 8, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company, today announced a presentation in

Alpine Immune Sciences Announces Participation in September Investor Conferences

Alpine Immune Sciences Announces Participation in September Investor Conferences Content Import Tue, 09/07/2021 - 16:06 Alpine Immune Sciences Announces Participation in September Investor Conferences September 7, 2021 This release is a backfill from a News W…

Alpine Immune Sciences Provides Corporate Update and Reports Second Quarter 2021 Financial Results

- Conference call and webcast today at 4:30 p.m. ET - SEATTLE --(BUSINESS WIRE)--Aug. 10, 2021-- Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today provided a

Alpine Immune Sciences to Report Second Quarter 2021 Financial Results and to Present at Upcoming Investor Conferences

SEATTLE --(BUSINESS WIRE)--Aug. 4, 2021-- Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will release second quarter 2021 financial
Show more

Alpine Immune Sciences Frequently Asked Questions

  • When was Alpine Immune Sciences founded?

    Alpine Immune Sciences was founded in 2015.

  • Who are Alpine Immune Sciences key executives?

    Alpine Immune Sciences's key executives are Mitchell H. Gold, Robert Conway and Min Cui.

  • How many employees does Alpine Immune Sciences have?

    Alpine Immune Sciences has 48 employees.

  • What is Alpine Immune Sciences revenue?

    Latest Alpine Immune Sciences annual revenue is $9.3 m.

  • What is Alpine Immune Sciences revenue per employee?

    Latest Alpine Immune Sciences revenue per employee is $194.5 k.

  • Who are Alpine Immune Sciences competitors?

    Competitors of Alpine Immune Sciences include Italfarmaco, EUSA Pharma and Chugai Pharmaceutical.

  • Where is Alpine Immune Sciences headquarters?

    Alpine Immune Sciences headquarters is located at 188 E Blaine St #200, Seattle.

  • Where are Alpine Immune Sciences offices?

    Alpine Immune Sciences has an office in Seattle.

  • How many offices does Alpine Immune Sciences have?

    Alpine Immune Sciences has 1 office.